Rankings
▼
Calendar
ICCC
ImmuCell Corporation
$60M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$8M
+11.2% YoY
Gross Profit
$3M
41.6% margin
Operating Income
$1M
13.9% margin
Net Income
$1M
17.9% margin
EPS (Diluted)
$0.16
QoQ Revenue Growth
+4.1%
Cash Flow
Operating Cash Flow
$2M
Free Cash Flow
$1M
Stock-Based Comp.
$52,215
Balance Sheet
Total Assets
$46M
Total Liabilities
$17M
Stockholders' Equity
$29M
Cash & Equivalents
$5M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$8M
$7M
+11.2%
Gross Profit
$3M
$2M
+46.1%
Operating Income
$1M
-$300,050
+472.5%
Net Income
$1M
-$437,868
+430.5%
Geographic Segments
UNITED STATES
$7M
100%
← FY 2025
All Quarters
Q2 2025 →
ICCC Q1 2025 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena